In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Evotec acquires Oxford Asymmetry

Executive Summary

Evotec BioSystems (develops drugs for unmet medical needs) has acquired Oxford Asymmetry International (UK discovery services company). Shareholders will receive 0.1287 of a new Evotec share for each OAI share, valuing the stock swap at $475mm (UK316mm). OAI shareholders will own about 31% of the new company.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies